The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).
Hidehito Horinouchi
No relevant relationships to disclose
Ikuo Sekine
No relevant relationships to disclose
Minako Sumi
No relevant relationships to disclose
Miyako Satouchi
Honoraria - Kyowa Hakko Kirin
Hiroshi Isobe
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Seiji Niho
No relevant relationships to disclose
Kiyoshi Mori
No relevant relationships to disclose
Tomohide Tamura
Honoraria - Bristol-Myers Squibb; Kyowa Hakko Kirin